Bayer Seeks To Ward Off Xarelto Infringers In India

Bayer presses on with legal action to fend off alleged infringers of its patent on Xarelto in India. A hearing is expected shortly in one such case, which seemingly includes a settlement option. The German multinational also remains engaged in a keenly contested and controversial case around India’s Bolar exemption provision - the experimental use or early working exception.